Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by 2O2Ovisionon Oct 28, 2023 9:16am
196 Views
Post# 35705531

RE:RE:RE:Roche for the buyout

RE:RE:RE:Roche for the buyoutAt the very least and for patients' sake, Pancan should be able to move this along quicker with its ongoing sites, FDA relationship, public support and lobbying etc than a corporate entity would. Roche certainly doesn't need a charity to run a trial for them but they will have a pretty clear investment case for their shareholders with the go-no-go decision in 2025 for a full PIII regardless of premium to be paid or ONC's long history. No one knows if it'll get that far without an accelerated approval, buyout, partnership or what have you, but that's the nature of a speculative play. I believe Roche won't let this get much further without getting involved somehow and as a shareholder I've made my wager, but you're right, until that press release comes out.......
<< Previous
Bullboard Posts
Next >>